Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)

Trial Profile

Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Ocular inflammation; Postoperative pain
  • Focus Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 05 Feb 2018 Primary endpoint has not been met. (Pain score = 0), according to an EyeGate Pharma media release.
    • 05 Feb 2018 Primary endpoint has not been met. (AC cell count = 0), according to an EyeGate Pharma media release.
    • 05 Feb 2018 Results published in an EyeGate Pharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top